HAVCR2 and acute myeloid leukemia: As previously described, TIM-3 is expressed on myeloid LSCs; thus, Kikushige Y et al. successfully reconstructed an AML model using TIM-3+ AML cells in immunodeficient mice and established the first anti-human TIM-3 mouse IgG2a mAb that did not disrupt the reconstitution of normal human HSCs but blocked LSCs [41].